Antitussive drugs-past, present, and future

Peter Vytautas Dicpinigaitis, A. H. Morice, S. S. Birring, L. McGarvey, J. A. Smith, B. J. Canning, C. P. Page

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Cough remains a serious unmet clinical problem, both as a symptom of a range of other conditions such as asthma, chronic obstructive pulmonary disease, gastroesophageal reflux, and as a problem in its own right in patients with chronic cough of unknown origin. This article reviews our current understanding of the pathogenesis of cough and the hypertussive state characterizing a number of diseases as well as reviewing the evidence for the different classes of antitussive drug currently in clinical use. For completeness, the review also discusses a number of major drug classes often clinically used to treat cough but that are not generally classified as antitussive drugs. We also reviewed a number of drug classes in various stages of development as antitussive drugs. Perhaps surprising for drugs used to treat such a common symptom, there is a paucity of well-controlled clinical studies documenting evidence for the use of many of the drug classes in use today, particularly those available over the counter. Nonetheless, there has been a considerable increase in our understanding of the cough reflex over the last decade that has led to a number of promising new targets for antitussive drugs being identified and thus giving some hope of new drugs being available in the not too distant future for the treatment of this often debilitating symptom.

Original languageEnglish (US)
Pages (from-to)468-512
Number of pages45
JournalPharmacological Reviews
Volume66
Issue number2
DOIs
StatePublished - Mar 26 2014

Fingerprint

Antitussive Agents
Cough
Pharmaceutical Preparations
Patient Rights
Gastroesophageal Reflux
Chronic Obstructive Pulmonary Disease
Reflex
Asthma

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Dicpinigaitis, P. V., Morice, A. H., Birring, S. S., McGarvey, L., Smith, J. A., Canning, B. J., & Page, C. P. (2014). Antitussive drugs-past, present, and future. Pharmacological Reviews, 66(2), 468-512. https://doi.org/10.1124/pr.111.005116

Antitussive drugs-past, present, and future. / Dicpinigaitis, Peter Vytautas; Morice, A. H.; Birring, S. S.; McGarvey, L.; Smith, J. A.; Canning, B. J.; Page, C. P.

In: Pharmacological Reviews, Vol. 66, No. 2, 26.03.2014, p. 468-512.

Research output: Contribution to journalArticle

Dicpinigaitis, PV, Morice, AH, Birring, SS, McGarvey, L, Smith, JA, Canning, BJ & Page, CP 2014, 'Antitussive drugs-past, present, and future', Pharmacological Reviews, vol. 66, no. 2, pp. 468-512. https://doi.org/10.1124/pr.111.005116
Dicpinigaitis PV, Morice AH, Birring SS, McGarvey L, Smith JA, Canning BJ et al. Antitussive drugs-past, present, and future. Pharmacological Reviews. 2014 Mar 26;66(2):468-512. https://doi.org/10.1124/pr.111.005116
Dicpinigaitis, Peter Vytautas ; Morice, A. H. ; Birring, S. S. ; McGarvey, L. ; Smith, J. A. ; Canning, B. J. ; Page, C. P. / Antitussive drugs-past, present, and future. In: Pharmacological Reviews. 2014 ; Vol. 66, No. 2. pp. 468-512.
@article{1f2401771bed411fb757208c085a7577,
title = "Antitussive drugs-past, present, and future",
abstract = "Cough remains a serious unmet clinical problem, both as a symptom of a range of other conditions such as asthma, chronic obstructive pulmonary disease, gastroesophageal reflux, and as a problem in its own right in patients with chronic cough of unknown origin. This article reviews our current understanding of the pathogenesis of cough and the hypertussive state characterizing a number of diseases as well as reviewing the evidence for the different classes of antitussive drug currently in clinical use. For completeness, the review also discusses a number of major drug classes often clinically used to treat cough but that are not generally classified as antitussive drugs. We also reviewed a number of drug classes in various stages of development as antitussive drugs. Perhaps surprising for drugs used to treat such a common symptom, there is a paucity of well-controlled clinical studies documenting evidence for the use of many of the drug classes in use today, particularly those available over the counter. Nonetheless, there has been a considerable increase in our understanding of the cough reflex over the last decade that has led to a number of promising new targets for antitussive drugs being identified and thus giving some hope of new drugs being available in the not too distant future for the treatment of this often debilitating symptom.",
author = "Dicpinigaitis, {Peter Vytautas} and Morice, {A. H.} and Birring, {S. S.} and L. McGarvey and Smith, {J. A.} and Canning, {B. J.} and Page, {C. P.}",
year = "2014",
month = "3",
day = "26",
doi = "10.1124/pr.111.005116",
language = "English (US)",
volume = "66",
pages = "468--512",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Antitussive drugs-past, present, and future

AU - Dicpinigaitis, Peter Vytautas

AU - Morice, A. H.

AU - Birring, S. S.

AU - McGarvey, L.

AU - Smith, J. A.

AU - Canning, B. J.

AU - Page, C. P.

PY - 2014/3/26

Y1 - 2014/3/26

N2 - Cough remains a serious unmet clinical problem, both as a symptom of a range of other conditions such as asthma, chronic obstructive pulmonary disease, gastroesophageal reflux, and as a problem in its own right in patients with chronic cough of unknown origin. This article reviews our current understanding of the pathogenesis of cough and the hypertussive state characterizing a number of diseases as well as reviewing the evidence for the different classes of antitussive drug currently in clinical use. For completeness, the review also discusses a number of major drug classes often clinically used to treat cough but that are not generally classified as antitussive drugs. We also reviewed a number of drug classes in various stages of development as antitussive drugs. Perhaps surprising for drugs used to treat such a common symptom, there is a paucity of well-controlled clinical studies documenting evidence for the use of many of the drug classes in use today, particularly those available over the counter. Nonetheless, there has been a considerable increase in our understanding of the cough reflex over the last decade that has led to a number of promising new targets for antitussive drugs being identified and thus giving some hope of new drugs being available in the not too distant future for the treatment of this often debilitating symptom.

AB - Cough remains a serious unmet clinical problem, both as a symptom of a range of other conditions such as asthma, chronic obstructive pulmonary disease, gastroesophageal reflux, and as a problem in its own right in patients with chronic cough of unknown origin. This article reviews our current understanding of the pathogenesis of cough and the hypertussive state characterizing a number of diseases as well as reviewing the evidence for the different classes of antitussive drug currently in clinical use. For completeness, the review also discusses a number of major drug classes often clinically used to treat cough but that are not generally classified as antitussive drugs. We also reviewed a number of drug classes in various stages of development as antitussive drugs. Perhaps surprising for drugs used to treat such a common symptom, there is a paucity of well-controlled clinical studies documenting evidence for the use of many of the drug classes in use today, particularly those available over the counter. Nonetheless, there has been a considerable increase in our understanding of the cough reflex over the last decade that has led to a number of promising new targets for antitussive drugs being identified and thus giving some hope of new drugs being available in the not too distant future for the treatment of this often debilitating symptom.

UR - http://www.scopus.com/inward/record.url?scp=84897537546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897537546&partnerID=8YFLogxK

U2 - 10.1124/pr.111.005116

DO - 10.1124/pr.111.005116

M3 - Article

C2 - 24671376

AN - SCOPUS:84897537546

VL - 66

SP - 468

EP - 512

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 2

ER -